Long-term multicenter experience with a second-generation implantable pacemaker-defibrillator in patients with malignant ventricular tachyarrhythmias  by Saksena, Sanjeev et al.
490 JACC Vol. 19, No.3
March I, 1992:490-9
Long-Term Multicenter Experience With a Second-Generation
Implantable Pacemaker-Defibrillator in Patients With Malignant
Ventricular Tachyarrhythmias
SANJEEV SAKSENA, MD, FACC, MARIA POCZOBUTT-JOHANOS,*
LON W. CASTLE, MD, FACC, RICHARD N. FOGOROS, MD, FACC,
BARRY L. ALPERT, MD, FACC, JACK KRON, MD, FACC, ANTONIO PACIFICO, MD, FACC,
JERRY GRIFFIN, MD, FACC, JEREMY N. RUSKIN, MD, FACC,
RICHARD F. KEHOE, MD, FACC, RAYMOND YEE, MD, FACC, PAUL DORIAN, MD, FACC,
CHARLES R. KERR, MD, FACC, RICHARD M. LUCERI, MD, FACC,
MICHAEL POLISENO,* FOR THE GUARDIAN MULTICENTER INVESTIGATORS GROUpt
A second-generation implantable pacemaker-cardioverter-
defibrillator was evaluated in 200 patients with sustained ventric-
ular tachycardia, ventricular fibrillation or prior cardiac arrest.
The device permits demand ventricular pacing for bradyarrhyth-
mias and for long QT interval or tachycardia suppression, uses
programmable (3 to 30 J) energy shocks for conversion of
ventricular tachycardia and ventricular fibrillation and is used
with conventional pacing and defibrillation leads. Ventricular
tachycardia/fibrillation recognition is based on the ventricular
electrogram rate and requires reconfirmation before shock deliv-
ery.
Two hundred patients (mean age 62 years, mean left ventric-
ular ejection fraction 36%) were enrolled and followed up for 0 to
23 months (mean 12). Epicardial lead system implantation was
performed with use of an anterolateral thoracotomy (38%),
median sternotomy (26 %) and subxiphoid (20%) or subcostal
(16%) approach. Perioperative mortality rate was 5.5% (all
nonarrhythmic deaths).
Implant defibrillation threshold ranged from 3 to 30 J (mean
Implantable cardioverter-defibrillator devices have been de-
veloped for automatic recognition and termination of sus-
tained ventricular tachyarrhythmias. These devices are now
available for general clinical use in patients resuscitated from
sudden cardiac arrest or symptomatic sustained ventricular
tachycardia. A variety of clinical and technologic concerns
have limited the use of this therapy (1). These include
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15), with initial programmed shock energy ranging from 3 to 30 J
(mean 22). Ventricular tachycardia/fibrillation sensing threshold
ranged from 0.7 to 1.8 mV (median 1) and the tachycardia
detection interval from 288 to 416 ms (median 320). Reprogram-
ming of implant variables was necessary for reliable electro-
graphic sensing (54 patients), programmed shock therapy (61
patients) and tachycardia detection rate (63 patients). Device
activation for potential shock delivery occurred in 111 patients
(55.5%) with actual shock delivery after ventricular tachycardia/
fibrillation reconfirmation in 66 patients (33%). During follow-up
study, there was a 1% arrhythmia mortality rate, 6.5% cardiac
mortality rate and 10.5% total mortality rate.
This study demonstrates that the programmable implantable
pacemakerocardioverter-defibrillator is effective in preventing ar-
rhythmic death, yet reduces patient exposure to repeated shock
therapy. Reprogramming is usually necessary during follow-up
for optimal function.
(J Am Coll CardioI1992;19:490-9)
absence of demand pacing for concomitant bradycardia, use
of high energy shocks for well tolerated hemodynamically
stable ventricular tachycardia in a conscious patient and
committed shock therapy in patients with nonsustained ar-
rhythmia (2). New technology seeks to address these issues.
In this report, we describe our initial clinical experience
with a second-generation programmable combination pace-
maker-cardioverter-defibrillator (models 4202 and 4203,
Telectronics Pacing Systems) used in conjunction with an
epicardial defibrillation lead system. To our knowledge, this
represents the first reported long-term clinical experience
with a combined pacemaker-defibrillator in a multicenter
trial. This multicenter report examines both the performance
of the device system and its clinical efficacy and safety in
patients with malignant ventricular tachyarrhythmias.
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Methods
Patient selection. Patients included in this study fulfilled
one or more of the following requirements. 1) They had
experienced one or more documented episodes of ventricu-
lar fibrillation that was unrelated to transient or reversible
clinical events. 2) They had drug-refractory sustained ven-
tricular tachycardia. Refractoriness was defined as sponta-
neous ventricular tachycardia recurrence, induction of ven-
tricular tachycardia at electrophysiologic study during the
period of drug administration or drug intolerance. 3) They
had a previously implanted cardioverter-defibrillator device
for the treatment of ventricular tachycardia or ventricular
fibrillation, were considered by the investigator to be at
continued risk for arrhythmia recurrence and required pulse
generator replacement for battery depletion. 4) They had a
previously implanted epicardial defibrillation lead system
and required cardioverter-defibrillator pulse generator im-
plantation for anticipated recurrence of sustained ventricular
tachycardia or ventricular fibrillation.
Patients were excluded from the study if any of the
following conditions were present. 1) Atrial flutter or fibril-
lation or supraventricular tachycardia with rapid ventricular
rates despite optimal antiarrhythmic drug therapy; 2) pres-
ence of drug-induced ventricular tachycardia or ventricular
fibrillation; 3) ventricular tachycardia or ventricular fibrilla-
tion related to metabolic or electrolyte abnormalities, acute
myocardial infarction of :51 month duration or acute myo-
cardial ischemia; 4) ventricular tachycardia rate lower than
the lowest programmable tachycardia detection rate for the
device or slower than the maximal rate during sinus tachy-
cardia; 5) presence of frequent nonsustained ventricular
tachycardia or incessant sustained ventricular tachycardia or
ventricular fibrillation (the definition of "frequent" and
"incessant" were left to the investigators' discretion);
6) inability of the patient to comply with device follow-up
procedures for medical or administrative reasons; and 7) life
expectancy of :56 months at the time of potential device
implantation.
Indications for use of concomitant pacing function im-
plantation included sinus bradycardia, atrioventricular (AV)
block, postcardioversion bradycardia, long QT interval and
possible suppression of tachycardia recurrence.
Written informed consent for study procedures and
follow-up requirements was obtained from each patient.
Approval of the study protocol was obtained from each
individual Institutional Review Committee for Human Re-
search and the U.S. Food and Drug Administration.
Study patients. During the period between February 1,
1989 and January 1, 1991,200 patients (159 male, 41 female)
were enrolled in this study in 14 participating institutions.
They ranged in age from 17 to 88 years (mean 62). Their
clinical presentation was sudden cardiac arrest in 87 pa-
tients, primary documented ventricular fibrillation in 16,
recurrent sustained ventricular tachycardia and ventricular
fibrillation in 17, and recurrent sustained ventricular tachy-
cardia in 80. Their associated cardiac diagnoses were coro-
nary artery disease in 136 patients, cardiomyopathy in 63,
valvular heart disease in 23, primary electrical disease in 5
and congenital heart disease in 1. Thirty patients had more
than one cardiac disease diagnosis. Other associated cardiac
conditions included systemic arterial hypertension in 33
patients (17%), congestive heart failure in 36 (18%), prior
coronary bypass surgery in 62 (31%) and prior valve surgery
in 9 (5%). The global left ventricular ejection fraction as
determined by radionuclide angiography, two-dimensional
echocardiography or cardiac catheterization ranged from
10% to 78% (mean 36%). The duration of patient follow-up
ranged from 0 to 23 months (mean 12).
Pulse generator and lead system. The implantable pulse
generators used in this study were Telectronics Guardian
models 4202 and 4203. These devices are multiprogramma-
ble pacemaker-cardioverter-defibrillators capable of pro-
grammable demand ventricular pacing and automatic ven-
tricular tachycardia and ventricular fibrillation recognition
and conversion using programmable (3 to 30 1) monophasic
shocks. A truncated exponential shock waveform is used
and a standard rectangular pacing stimulus waveform is
employed. Additional features include tachycardia reconfir-
mation before shock delivery and device memory for total
shock activations and actual patient shocks delivered. A
series of seven shocks can be delivered in response to
ventricular tachycardia or ventricular fibrillation. Several
preset incremental shock protocols, selected by the initial
programmed shock energy, are available. Marker channel
and intracardiac electrogram signals can be obtained by
radiofrequency telemetric link with either a programmable
external pacemaker-cardioverter-defibrillator (Telectronics
model 4502 or 4510) or an external programmer (Telectronics
model 4810). The pulse generator is currently used in con-
junction with a wholly or modified epicardial lead system.
The external pacemaker-cardioverter-defibrillator (Telec-
tronics model 4502 or 4510) incorporates all features of the
implanted pulse generator. In addition, it includes an alter-
nating current fibrillator for induction of ventricular tachy-
cardia and ventricular fibrillation and a maximal shock
output sequence that delivers a maximal energy shock (30 J)
for emergency conversion of ventricular tachycardia/
fibrillation, bypassing the preset incremental protocol. The
device also has a maximal shock activated by the program-
mer. It permits monitoring of the marker channel and
tachycardia electrograms on a dedicated multichannel dis-
play recorder.
The external programmer (Telectronics model 4810) per-
mits selection of variables for demand pacing, sensing and
tachycardia detection and conversion. It establishes a radio-
frequency telemetric link with use of a programmer wand.
This permits device interrogation and is accompanied by a
printer for obtaining hardcopy printouts.
On the basis of external device testing, the investigator
selects the programmable variables for the implantable pulse
generator. Demand pacing rates vary from 30 to 75 beats/
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min, and the tachycardia detection intervals from 416 to
288 ms. The initial shock energy is programmable from 3 to
30 1. The initial shock energy defines one of several incre-
mental shock protocols that are available for the series of
seven shocks delivered by the device. In all series, the last
four shocks are always at maximal device output (30 J).
Lower initial shock energies are generally recommended for
ventricular tachycardia cardioversion or in patients with low
defibrillation threshold values.
Implantation. The study design required entry ofpatients
who met inclusion and exclusion criteria and were willing to
undergo electrophysiologic evaluation before, during and
after device implantation. All patients underwent baseline
electrophysiologic evaluation with use of standard tech-
niques for ventricular tachycardia and ventricular fibrillation
(3). These studies were usually performed with patients in
the drug-free state. Patients were selected for device implan-
tation after written informed consent was obtained.
The implantation procedure was performed with use of
previously described surgical techniques (4,5). Surgical im-
plantation of the lead system was accomplished under gen-
eral anesthesia by thoracotomy or sternotomy. The lead
system usually had two components.
1. Cardioversion-defibrillation leads. Two electrodes,
either two epicardial patch electrodes (model A67, L67,
Cardiac Pacemakers Inc. [CPI] or Telectronics model 040-
105,040-106,040-107) or one epicardial patch electrode and
one endocardial spring defibrillation electrode (CPI model
ClO), were employed. The patch electrodes were placed
intrapericardially or extrapericardially over the right or left
ventricle, or both, and the spring electrode was placed in the
superior vena cava or right atrium.
2. Bipolar sensing and pacing lead system. Two myo-
cardial screw-in or stab-in electrodes (Telectronics model
030-168 or Medtronic model 4951, respectively) or a bipolar
endocardial catheter electrode (model BT-lO, CPI) were
utilized. The myocardial electrodes were placed on the right
or left ventricle separated by an interelectrode distance of 1
to 2 cm. When used, the endocardial electrode was posi-
tioned in the right ventricular apex.
Intraoperative testing. Leads. After lead placement, intra-
operative testing using the external cardioverter-defibrillator
included the following.
Defibrillation threshold testing. Ventricular fibrillation
was induced with use of alternating current or pacing tech-
niques. After induction, ventricular fibrillation was main-
tained for;::: 10 s before the test shock was delivered. The test
shock utilized a monophasic truncated exponential wave-
form; stored energy ranged from 3 to 30 J at the investiga-
tors' discretion. If the shock was successful, the shock
energy level could be increased or decreased in steps of
;:::3 1. The defibrillation threshold was defined as the lowest
successful energy level for ventricular fibrillation termina-
tion. Three consecutive successful terminations of ventricu-
lar fibrillation at this energy level were required to define the
defibrillation unless these conditions were precluded by the
patient's clinical status or if ventricular fibrillation could not
be induced by standard induction methods. If the test shock
was unsuccessful, a high energy rescue shock was delivered
with use of the defibrillation lead system or intrathoracic or
transthoracic electrodes connected to a conventional exter-
nal defibrillator. Subsequently, ventricular fibrillation was
reinduced and the efficacy of a higher energy shock was
tested with use of the defibrillation lead system. In all
patients, attempts to induce ventricular fibrillation were
mandatory. A safety margin of ;:::10 J between the defibril-
lation threshold and the maximal output of the device (30 1)
was preferred. Ventricular tachycardia cardioversion was
evaluated when lower energy shock cardioversion therapy
was being considered.
Sensing threshold test. The sensing electrogram ampli-
tude could be directly measured by standard techniques
during sinus rhythm if the electrode was directly connected
to recording equipment and a marker channel signal indi-
cated sensed events. Sensed events were evaluated during
sinus rhythm, induced ventricular fibrillation and, if indi-
cated, ventricular tachycardia. The sensing threshold and
tachycardia detection rate were programmed before arrhyth-
mia induction. Tachycardia detection could be analyzed by
using the marker channel and intracardiac electrogram sig-
nals. Tachycardia detection occurred when 6 of7 or 12 of 14
consecutive sensed events satisfied the programmed detec-
tion rate criterion. Adequate detection during ventricular
fibrillation was mandatory and repetitive nonsensing or
oversensing required reprogramming of the sensing thresh-
old. Pacing threshold and lead impedance during sinus
rhythm were evaluated with standard techniques. Pacing
threshold was defined as the lowest stimulus output at I-ms
pulse width obtained with a rectangular pulse waveform
producing consistent I: 1 ventricular pacing.
Implantable defibrillator system test. The implanted
pulse generator was placed in a standard abdominal pocket
created in the anterior abdominal wall in a paraumbilical or
left subcostal location. The lead system was tunneled to this
pocket. Model 4202 was connected to the CPI leads,
whereas model 4203 used Telectronics leads. Both pulse
generators were comparable in all other respects and deliv-
ered synchronized shocks. After placement in the pocket, a
sterile programmer wand was placed over the generator and
used to establish a telemetric link with an external program-
mer (Telectronics model 4810). The pulse generator was
programmed for the selected variables and placed in an
inactive mode during arrhythmia induction. Ventricular
fibrillation was induced and the device was activated with
use of the programmer and the previously positioned wand.
Automatic recognition and shock delivery by the implanted
pulse generator and lead system were evaluated. Successful
detection of ventricular fibrillation and conversion with the
programmed variables were sought. If these were unsuccess-
ful, device reprogramming or lead repositioning, or both,
was performed as determined by the investigator. Demand
pacing/sensing during sinus rhythm, sensing during ventric-
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Figure 1. Initial programming and reprogramming of the Telectron-
ics 4202 and 4203 implantable pacemaker-defibrillator at electro-
physiologic testing (EPS). The percent of patients in the total study
group with the device programmed to individual values in the ranges
shown are indicated by the bars. A, Programming ofthe tachycardia
detection interval at electrophysiologic testing during implantation
(IMPLANT), before hospital discharge (PREDISCHARGE) and at
long-term follow-up study (CHRONIC). There is a shift toward
longer tachycardia detection intervals over long-term follow-up. B,
Programming of the sensing threshold based on ventricular electro-
graphic amplitude for the periods shown in A. Note the gradual shift
toward values <1.8 mY and predominantly toward <1 mY. C,
Programmed initial shock energy during the periods shown in Aand
B. Note the shift toward progressively higher initial shock energy
levels, which are >20 J in the majority of patients during long-term
follow-up.
ular tachycardia or ventricular fibrillation and pacing/sensing
after shock delivery were also examined, Device reprogram-
ming or lead repositioning was undertaken if this function
was unsatisfactory.
Postoperative care. All patients underwent postoperative
cardiac monitoring. This included continuous telemetric
and, if indicated, ambulatory 24-h electrocardiographic
(ECG) monitoring before discharge.
Predischarge electrophysiologic study. This evaluation
was performed 5 to 14 days after device and lead system
implantation on the discharge drug regimen. Electrophysio-
logic evaluation included induction of ventricular fibrillation
and evaluation of the implanted device and lead system using
methods identical to those used the implant test. If indicated,
reprogramming was performed for programmable variables.
Unsatisfactory performance with respect to pacing, sensing,
ventricular tachycardia/fibrillation detection or reversion
despite reprogramming mandated revision of the antiar-
rhythmic drug regimen or lead system, or both. If the system
performance was satisfactory, the patient was discharged to
outpatient follow-up.
Outpatient follow-up. This included clinic visits at 1
month and every 2months thereafter. Aclinical examination
was performed. The pulse generator was interrogated at
each visit. Programmed variables, device activation, shock
delivery to the patient, pacing and sensing thresholds were
evaluated. Twenty-four hour ambulatory ECG monitoring
and exercise testing were performed as indicated (for exam-
ple, for multiple device activations or potentially inappropri-
ate shock delivery). During follow-up, patients were re-
quired to report spontaneous shock delivery or symptomatic
events (for example, palpitation, syncope or presyncope).
Hospital admissions for frequent ventricular tachycardia/
fibrillation or shock delivery were examined. Analysis of
perioperative death (defined as any death occurring within 30
days of implantation) and total, cardiac and arrhythmic
mortality rates was performed.
Late electrophysiologic study. A delayed electrophysio-
logic evaluation was performed 2 to 4 months after implan-
tation to assess the long-term performance of the system.
Standard electrophysiologic techniques were used for the
procedure. System testing was identical to that in the im-
plantation and predischarge electrophysiologic evaluation.
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Results
Early results (Fig. 1). Primary pulse generator and lead
system implantation were performed in 181 patients, with a
secondary pulse generator replacement procedure under-
taken in 19 patients. The surgical approach employed for
primary device implantation was a left anterolateral thora-
cotomy in 68 patients, a median sternotomy in 47, a subxi-
phoid approach in 37 and a subcostal approach in 29.
The pacing threshold at implantation ranged from 0.1 to
3.9 V (mean 1.4) at I-ms stimulus pulse width. The selected
tachycardia detection intervals at implantation ranged from
c
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Figure 3. Device activation during follow-up in the study patients.
Note that >50% of the patients experience device activation for
nonsustained or sustained arrhythmia during the follow-up period.
Pre.sence of reconfirmation prevented shock delivery in 41% of
patIents on one or more occasions.
30266
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Figure 2. Long-term survival of the study patients assessed with a
Kaplan-Meier life table survival analysis. Arrhythmic, cardiac and
total deaths are plotted over the follow-up period of 2 years.
288 to 416 ms (median 320) (Fig. lA) and the sensing
thresholds ranged from 0.7 to 1.8 mV (median 1) (Fig. IB). In
the majority of patients programming at implantation used
sensing thresholds of 1 to 1.8 mV and tachycardia detection
intervals of 300 to 400 ms. The defibrillation threshold at
device implantation ranged from 3 to 30 J (mean 15.6). On
the basis of these observations, programmed initial shock
energy ranged from 3 to 30 J (median 30; mean 22.1). The
proportion of patients at different levels of initial shock
energies is shown in Figure 1C. The selected initial shock
energies exceeded the mean defibrillation threshold by an
average of 6.5 J.
Follow-up results. Analysis ofpatient survival and device
performance (Fig. 2). The perioperative mortality rate was
5.5%. Table 1 categorizes the causes of perioperative and
late deaths in this group of patients during the study period.
Note that perioperative death is nearly equally attributed to
nonarrhythmic cardiac and noncardiac causes. The late
mortality is largely due to nonarrhythmic cardiac causes (for
example, congestive heart failure or myocardial infarction)
and to a lesser extent, noncardiac causes. Arrhythmic deaths
were uncommon. There were no known bradyarrhythmic
deaths; sudden death occurred in two patients.
Implantable cardioverter-defibrillator function is summa-
rized in Figure 3. During the follow-up period, the device
was charged for potential shock delivery in III patients
(56%). In 66 ofthese III patients (33% of the total group) the
shock was actually delivered after tachycardia reconfirma-
tion. In 45 patients (23%) the shock was discharged inter-
nally after tachycardia persistence was not reconfirmed.
Both shock delivery and internal shock discharge occurred
in 37 patients. The device was not activated during follow-up
in 89 patients.
Reprogramming. Reprogramming of device variables for
pacing, sensing, tachycardia detection rate and initial shock
energy was performed at predischarge or late electrophysi-
ologic study and during outpatient follow-up (Fig. 1, 2 and
4). In general, the sensing threshold was unchanged or
reprogrammed to lower values in 54 patients (usually 0.7 or
1 mV) to achieve satisfactory ventricular tachycardiaJ
fibrillation recognition (Fig. 4 and 5). Programmed tachycar-
dia detection rate was programmed to longer intervals at
preimplantation or follow-up electrophysiologic study in 38
patients or to shorter intervals in 25 patients (Fig. 5). The
Figure 4. Reprogramming of the implantable cardioverter-
defibrillator during the 1st 6 months of follow-up. At 6-month
follow-up, the proportion of patients whose device had one or more
rep~ogramming of three variables, the ventricular tachycardia de-
tectJ?n (VT DETECT) interval, the initial shock energy and the
sensmg thr~shold are shown. Note that reprogramming for one or
more variables is frequently required for optimal function.
# PATIENTS1401------------------~
120
Table 1. Early and Late Mortality in 200 Patients 100
No. of Patients 80
Perioperative 3D-day mortality
Arrhythmic
Cardiac
Total
Follow-up mortality (:523 months\
Arrhythmic
Cardiac
Total
1(0.5%)
7 (3.5%)
II (5.5%)
2 (1%)
13 (6.5%)
21 (10.5%)
80
VT DETECT INTER"'L INITIAL SHOCK ENERGY SENSING THRESHOLD
_ INCREASED _ REDUCED 0 UNCHANGED
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latter is the increase in pacing threshold in 17 patients with
the epicardial bipolar electrode system. In seven patients,
complete loss of capture by the pacing stimulus was noted,
Although usually transient, this required reprogramming for
correction in 10 patients and lead revision in 8patients. Loss
of sensing was observed in nine patients; it was resolved by
reprogramming in six and required lead revision, usually to
an endocardial system, in three. An increase in defibrillation
threshold and lead dislodgment or fracture were uncommon
on follow-up evaluation. Device-device interaction between
a previously implanted antitachycardia pacemaker and the
Guardian model 4202 or 4203 resulting in repetitive activa-
tion of the implantable cardioverter-defibrillator system was
managed by inactivation of the pacemaker device.
Table 2. Implantable Cardioverter-Defibrillator System-
Related Complications
median tachycardia detection interval was 352 ms, (range
288 to 416) at 6-month follow-up study, Initial shock energy
was reprogrammed to lower values in 21 patients and to
higher values in 40 patients (Fig. 5). The mean initial shock
energy was 22.6 J (range 3to 30) at 6-month follow-up study.
Implantable cardioverter-defibrillator system-related
complications (Table 2). These complications included mi-
nor technical as well as lead-related problems. Of note in the
Figure 5. Implantable cardioverter-defibrillator function during
electrophysiologic testing after lead replacement. Failure to sense
was initially noted during ventricular fibrillation and use of an
endocardial lead system at a sensing threshold ofO.? mV results in
I: I sensing during ventricular fibrillation (shown above). Reprogram-
ming to the highest sensitivity value was necessary in this patient to
achieve optimal sensing during ventricular fibrillation. The delivered
shock (right) terminated ventricular fibrillation with three repetitive
complexes after the shock before conversion to sinus rhythm after a
pause. ICECG '" intracardiac electrogram; MTE '" marker channel
showing main timing events.
Pulse generator (2%)
Loose set screw
Premature battery depletion
Lead system (10%)
Lead fracture
Lead dislodgment (endocardial sensor)
Patch buckling
Increase in defibrillation threshold
Increase in pacing threshold
With loss of capture
Oversensing
Combined or unresolved (1.5%)
Unresolved loss of sensing
Programmer (2%)
Loss of telemetry
Fibrillator switch fault
Incorrect programming (operator error)
Device-device interactions (1.5%)
No. of
Complications
2
2
4
I
I
4
17
10
2
I
I
2
3
Discussion
The development of hybrid pacemaker-cardioverter-
defibrillator devices has been envisioned for some time (6,7).
This study describes a multicenter investigation of the clin-
ical experience with one such device with bradycardia
pacing, cardioversion and defibrillation capabilities. Most
prior clinical investigations (8-12) with nonprogrammable
cardioverter-defibrillators have been reported by individual
investigators or in a data base registry format from manu-
facturers or voluntary sources. Prospective multicenter
studies are now being developed for second- and third-
generation programmable devices. Such trials reduce bias
with respect to individual patient groups, implants and
follow-up techniques. Previous outcome data have often not
included perioperative outcome data and have focused
largely on sudden death rates. An intention to treat analysis
has been suggested to permit standardization of clinical
outcome analysis in antiarrhythmic therapies. This multi-
center investigation provides such information in this type of
format for one multiprogrammable implantable pacemaker-
defibrillator.
Advantages. Because implantable and multiprogramma-
ble pacemaker-cardioverter-defibrillators have many poten-
tial advantages, both demand and even antitachycardia
pacemakers and nonprogrammable cardioverter-defibrilla-
tors have been implanted (12,13). Rapid ventricular pacing
and low energy shocks have both been reported (14) to be
effective for ventricular tachycardia cardioversion. Thus,
one potential advantage of such a combination device is
reduction in the need for high energy shock therapy, partic-
ularly in patients with hemodynamically stable, nonsyncopal
ventricular tachycardia (7). This feature could also increase
patient acceptance of electrical device therapy for ventricu-
lar tachyarrhythmia termination. Many patients can also
have coexisting primary bradyarrhythmias or develop drug-
induced bradyarrhythmias. Often they have compromised
ventricular function and the occurrence of bradycardia can
be deleterious in its management. The actual magnitude of
the need for demand pacing and thus the importance of this
feature remain unknown. In one series (12), this has been
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reported to be 5%. In controlled studies (14) of endocardial
cardioversion, prolonged bradycardia after tachycardia ter-
mination occurred in only 3% of episodes. However, in an
uncontrolled clinical series (15), bradyarrhythmic death may
account for a significant proportion of the small arrhythmic
mortality rate observed in patients with an implantable
cardioverter-defibrillator.
Comparison with previous devices. We found that hybrid
cardioverter-defibrillator implantation can be successfully
performed with comparable risk with that in patients receiv-
ing a nonprogrammable implantable cardioverter-defibril-
lator (2,12,16). Observed defibrillation thresholds were sim-
ilar to previous reported (8-10) values for dual epicardial
electrode systems. This is not surprising because similar or
identical defibrillation lead systems were used. Epicardial
pacing could be accomplished successfully in all patients at
implant. During follow-up, successful cardioversion and
defibrillation of induced ventricular tachycardia and ventric-
ular fibrillation by the Guardian model 4202 or 4203 was
demonstrated at predischarge and late electrophysiologic
study. Spontaneous device activation rates are comparable
with those in previous reports (7-12,17,18) in the first 2years
of follow-up. Actuarial analysis shows a progressive in-
crease in device use over the first 3 years, with a gradual
plateau in active device recruitment thereafter. Longer fol-
low-up analysis shows that 70% to 80% of all implanted
devices are eventually utilized by patients. However, shock
delivery has been determined to be for causes other than
sustained ventricular tachycardia or ventricular fibrillation
(supraventricular arrhythmias or nonsustained ventricular
tachycardia) in ~ 10% to 28% of patients with a nonprogram-
mabie device (9,17). This report confirms such estimates
because 41 % of patients experienced one or more device
charge sequence that was successfully aborted after recon-
firmation. This higher figure could be representative of the
incidence of supraventricular or nonsustained ventricular
arrhythmias in these patients or more likely in part to
satisfaction of abbreviated tachycardia detection criteria.
Bradycardia pacing was used by many patients, but exact
estimates of usage during the follow-up period are unavail-
able because of the absence of prolonged and repeated
ambulatory ECG monitoring. Clinical experience suggests
that this feature is often used after shock delivery or in
follow-up, even though it may not be essential to prevent
sudden death in many patients. Absence of sudden deaths
attributable to bradycardia indirectly supports the value of
this feature.
Long-term outcome. The long-term clinical outcome of
patients with programmable hybrid implantable cardio-
verter-defibrillators can be assessed. There has been ongoing
controversy (19) as to whether the benefits of implantable
cardioverter-defibrillator therapy with respect to long-term
patient survival have been overestimated. Perioperative risk
was a significant contributor to overall mortality and mor-
bidity in this study, accounting for 525% of the total patient
deaths in the first 2 years after implantation. Reduction of
this risk with the use of endocardial lead systems may
improve survival rates (7). Subsequent follow-up confirmed
virtual elimination of sudden death in the first 2 years after
hospital discharge, but a small but significant patient attrition
rate persisted as a result of noncardiac or nonarrhythmic
cardiac causes. This observation is comparable to previous
findings and appears to define limits to survival benefits with
implantable cardioverter-defibrillator devices in these el-
derly patients with significant progressive cardiac or other
concomitant diseases. The quantitative impact of the im-
plantable cardioverter-defibrillator on cardiovascular mor-
tality or total mortality rates cannot be assessed in this
study, which was not designed to include a control group.
However, these data do not provide any evidence for
increased patient risk with the availability of programmable
tachycardia detection and therapy variables. Finally, there
were no deaths due to bradyarrhythmia, which are reported
to account for up to 5% of mortality in some series (15,20).
The behavior of initially programmed variables during
follow-up was carefully studied and provides guidelines for
the clinical use of programmable devices. Epicardial pacing
thresholds increased and usually resulted in the need for
reprogramming in 5% of patients and loss of capture in 6%
early after implantation. Although these episodes were often
transient, these data do suggest need for alternative pacing
lead systems. Endocardial lead systems have been used in
such patients (21) or improved epicardial systems may be
devised. Such systems are particularly necessary with the
incorporation of antitachycardia pacing therapy for conver-
sion of ventricular tachycardia (22).
Tachycardia-sensing problems. Tachycardia detection in
nonprogrammable cardioverter-defibrillators is based on a
preselected tachycardia detection rate at the time of device
manufacture and information regarding the exact events at
the time of tachycardia detection is often unavailable even
though a marker channel can be obtained. Although auto-
matic gain control is present in the conventionally approved
device and is reported to sense electrographic amplitudes
~O.5 mV, the exact number of ventricular electrograms
sensed or ignored in any tachycardia sequence and the time
required to achieve reliable sensing have not been generally
known. This study has demonstrated that undersensing does
occur during induction of ventricular fibrillation at electro-
graphic thresholds >1 mV during long-term follow-up.
Long-term effective epicardial sensing thresholds usually
ranged from 0.7 to 1.4 mY. Programmed values of 0.7 to
1mVwere most commonly used during long-term follow-up;
thus, higher values should be avoided. This observation is
consistent with electrographic amplitude data (23) that sug-
gest that amplitudes of some ventricular fibrillation electro-
grams may often be < I mV. The extent of intrinsic variabil-
ity in ventricular fibrillation electrographic amplitude in
consecutive episodes is unknown, although repeated testing
has been recommended (23). Our experience (21,22) sug-
gests that programmable devices should provide sensing
amplitude variables <1mVand that a sensing safety margin
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should be considered at the time of implantation. In fixed
amplitude devices, late testing is valuable and recom-
mended. Changes in tachycardia sensing due to tachycardia
rate, configuration, concomitant drug therapy or ischemia
can greatly influence sensing. The presence of a safety
margin allows for these variables. Furthermore, detection of
ventricular tachycardia does not predict reliable detection of
ventricular fibrillation, and follow-up device evaluation
should include testing of both arrhythmias (23). Evaluation
of ventricular tachycardia sensing is also necessary because
variables selected for ventricular fibrillation detection could
conceivably result in oversensing or double sensing of larger
amplitude ventricular tachycardia electrograms (23).
Tachycardia detection rate criteria. These were often
revised during the follow-up period. Rate criteria were
revised to either longer cycle lengths for slower spontaneous
ventricular tachyarrhythmia rates or the required number of
sensed electrograms was increased to avoid repeated device
charging for nonsustained arrhythmias. Thus, it may be
desirable at implantation to choose longer detection cycle
lengths than suggested by individual rhythms, with >10
electrograms in the detection sequence as ageneral guideline
for accurate spontaneous sustained arrhythmia detection. It
has been previously demonstrated (24-26) that spontaneous
tachycardia events are slower than induced tachycardias in
the electrophysiologic laboratory. The correlation between
the programmed stimulation mode used and the spontaneous
tachycardia rate should be considered in selection of this
variable. In general, single and double ventricular extrastim-
uli more closely reproduce the spontaneous tachycardia
rate, whereas the use of burst pacing and three or more
extrastimuli has been reported (24,25) to shorten induced
tachycardia cycle lengths by 30 to 50 ms over the spontane-
ous tachycardia cycle length. Reprogramming of sensing
variables may also be necessary at predischarge electrophys-
iologic testing or during follow-up study to achieve a balance
between reliable tachycardia and fibrillation sensing and
oversensing in sinus rhythm or supraventricular tachycardia.
Changes in antiarrhythmic drug therapy or intercurrent
events such as ischemia or electrolyte imbalance should
prompt reassessment of tachycardia sensing.
Shock energy selection. Initial shock energy was repro-
grammed in 31% of patients, most often toward slightly
higher values. Initial shocks of :510 J were used in :515% of
our patients. Battery longevity is unlikely to be prolonged by
use of shocks in the 10 to 30 J range. Charging time,
reliability of ventricular tachycardia/fibrillation termination
and patient comfort remain the significant considerations in
the use of shocks in this range. The delivery of ineffective or
even proarrhythmic shocks in ventricular fibrillation or
ventricular tachycardia, respectively delaying high energy
shock delivery, has the potential for a marked increase in
defibrillation energy requirements and patient risk (27).
However, clinical outcome data in this report do not provide
evidence for any increase in sudden death rates with this
programmable device. The pattern of use of electrical ther-
apy other than high energy shocks for tachycardia termina-
tion can also be assessed to some extent. In previous
short-term studies (14), low energy shock therapy has been
found to be as effective for rapid ventricular pacing as
termination of ventricular tachycardia. At device implanta-
tion, initial shock energy was programmed in most instances
at >20 J, although approximately 30% of patients had lower
initial shock energies. It appears that selection of initial
shock energy was influenced to a greater extent by the
defibrillation threshold than the cardioversion energy. Be-
cause 55% of our patients had documented ventricular
fibrillation or sudden cardiac arrest during follow-up, a
significant percent (20%) had their device reprogrammed to
higher initial shock energies. This result may also reflect
elevation of defibrillation threshold during long-term follow-
up in selected patients. Thus, the use of low energy shocks
for ventricular tachycardia termination as an initial mode of
therapy was restricted to a minority of patients. Although
tolerance for low energy shocks of <2 J has been reported
(13,28) to be better than for high energy shocks, many
patients often perceive these shocks as painful.
Complications. Specific adverse effects expected or
noted in this study merit discussion. Although pacemaker-
defibrillator interactions previously observed (29) were elim-
inated, concern existed regarding the availability of only
single chamber pacing in this group of patients. Pacemaker
syndrome was not observed in this study. Any observed
worsening of congestive heart failure was not directly attrib-
utable to the VVI pacing mode. This finding is surprising and
merits continued observation. In one patient with a dual-
chamber AV sequential pacemaker, we reprogrammed the
device to single-chamber atrial pacing to avoid device-device
interaction while maintaining an AV sequential rhythm. We
noted with concern the limitations of long-term epicardial
ventricular pacing in our study. Endocardial leads for pacing
and sensing during ventricular tachycardia/fibrillation are
probably superior and it is preferable to consider placement
of an endocardial rate-sensing and pacing electrode for
pacemaker-cardioverter-defibrillator pulse generators (23,
30). Other complications with this device system are similar
to those reported (12) for other device and lead systems.
These are most often related to the need for a thoracotomy
procedure. Hardware reliability was comparable with that
for previous systems (12).
Clinical advantages. The patient served by this pacemak-
er-cardioverter-defibrillator remains comparable to patients
receiving nonprogrammable cardioverter-defibrillators. It
has been suggested that hybrid second- and third-generation
pacemaker-cardioverter-defibrillators will be able to be used
by patients with more frequent tachycardia recurrences,
particularly nonsustained and hemodynamically stable ven-
tricular tachycardia.
The availability of programming permitted management
of several clinical situations, including changes in arrhyth-
mia recurrence rates, frequent nonsustained arrhythmias,
increases in defibrillation or cardioversion thresholds and
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oversensing or undersensing. This ability ultimately reduced
the need for system revision by surgical intervention. Pro-
grammability will increase the complexity of the implanta-
tion and follow-up procedures but it may reduce overall
costs associated with nonsurgical management of clinical
problems related to the implanted device and leads by using
reprogramming. The present device has preset incremental
shock algorithms that, when inappropriately selected, could
result in prolonged ventricular tachycardia and ventricular
fibrillation episodes. However, in our analysis, there was no
significant arrhythmic mortality in the early follow-up period
and the preset rhythms may result in investigator bias
toward the use of higher energy initial shocks. The presence
of a preset shock algorithm also limits programming flexi-
bility. Flexible programming of the initial series of shocks
will further improve the selection of individualized therapy.
Conclusions. The initial clinical experience with this
pacemaker-cardioverter-defibrillator pulse generator pro-
vides significant new insight into the advantages of a hybrid
device and emphasizes the need for more detailed evaluation
of the device and lead system at the time of implantation and
the increasing complexities of implantable cardioverter-
defibrillator follow-up. Several new clinical issues specific to
such devices can be expected to arise during patient follow-
up. When such devices are interfaced with appropriate lead
systems, some of the current limitations of electrical therapy
in the treatment of ventricular tachyarrhythmias should be
overcome.
We gratefully acknowledge the assistance of Ina Ellen Wendler in preparation
of the manuscript.
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